Robert Winkler

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

Marianne Pavel, John D. Hainsworth, Éric Baudin et al. · The Lancet · 2011 · 1K citations

Carcinoid Syndrome, Octreotide Long-acting Repeatable, Medicine +8

Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial

Kohei Shitara, Toshihiko Doi, Mikhail Dvorkin et al. · The Lancet Oncology · 2018 · 495 citations

Gastrointestinal Oncology, Trifluridine/tipiracil Versus Placebo, Medicine +9

The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer

Eric Van Cutsem, R. Mayer, Stéphanie Laurent et al. · European Journal of Cancer · 2017 · 94 citations · Full text

Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors

Funda Meric‐Bernstam, Hendrik-Tobias Arkenau, Ben Tran et al. · Annals of Oncology · 2018 · 65 citations · Full text

Fgfr Pathway Alterations, Fgf/fgfr Aberrations, Fgfr Aberrations +19

Long‐term follow‐up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver‐related complications

Pierre Pradat, Hans L. Tillmann, Sílvia Sauleda et al. · Journal of Viral Hepatitis · 2006 · 60 citations